Immuron (IMRN) AI Stock Analysis

• Market Cap: $9.94M
• Dividend Yield: N/A
• Average Volume (3M): 20.03K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.04
• Revenue Growth: 82.77%
• EPS Growth: -87.95%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -0.85
• Shares Outstanding: 5,842,663
• 10 Day Avg. Volume: 12,134
• 30 Day Avg. Volume: 20,027
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Immuron's overall stock score is impacted primarily by strong revenue growth yet poor profitability, as reflected in its financial performance. The technical analysis provides a neutral outlook with no strong upward or downward momentum. Valuation is a concern given the negative earnings and lack of dividend yield, making it less attractive to value-focused investors.

Immuron Business Overview & Revenue Model

Company Description

Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.

How the Company Makes Money

Immuron generates revenue primarily through sales of its over-the-counter product Travelan, which is marketed to travelers seeking to prevent diarrhea caused by food and waterborne bacteria. Additionally, the company earns income from government and private sector research grants aimed at advancing its therapeutic candidates. Immuron also engages in strategic partnerships and licensing agreements with other pharmaceutical companies to co-develop and commercialize its products globally. These collaborations provide upfront payments, milestone payments, and royalties, contributing to the company's overall revenue stream.

Immuron Financial Statement Overview

Summary

Immuron demonstrates strong revenue growth, but profitability remains a major challenge with significant net losses and negative operating margins. The company maintains a solid equity position with minimal debt, providing a buffer against financial instability. However, weak cash flow performance raises concerns about liquidity and the ability to sustain operations without external financing.

Income Statement

The company has shown a significant increase in revenue over the past year, with a revenue growth rate of 171.7%. However, profitability remains a challenge as evidenced by the negative net profit margin of -141.5% and consistently negative EBIT and EBITDA margins. The gross profit margin is relatively strong at 68.1%, indicating good control over direct costs, but overall profitability is heavily impacted by high operating expenses.

Balance Sheet

The balance sheet exhibits financial stability with a low debt-to-equity ratio of 0.01, suggesting minimal leverage. However, the return on equity is negative at -54.6%, reflecting the company's struggle to generate profits from shareholder investments. The equity ratio stands at 81.7%, indicating a strong equity position relative to total assets, which provides some financial resilience.

Cash Flow

Cash flow performance is weak, with a negative operating cash flow to net income ratio, indicating that the company is not generating enough cash from operations to cover its net income loss. Free cash flow is also negative, and the free cash flow growth rate is -113.7%, showing a declining trend in cash available after capital expenditures.

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
4.90M	1.80M	765.19K	145.78K	2.52M
	Gross Profit
3.34M	1.31M	523.50K	94.70K	1.83M
	EBIT
-5.80M	-6.00M	-4.06M	-8.41M	-3.39M
	EBITDA
-6.88M	-3.80M	-3.08M	-8.33M	-3.17M
	Net Income Common Stockholders
-6.94M	-3.79M	-2.85M	-8.38M	-2.93M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
11.66M	18.99M	22.11M	25.05M	3.25M
	Total Assets
15.55M	21.99M	24.86M	27.05M	6.20M
	Total Debt
173.50K	189.09K	209.79K	20.50K	61.10K
	Net Debt
-11.48M	-16.97M	-21.90M	-25.03M	-3.19M
	Total Liabilities
2.84M	2.37M	1.68M	1.16M	558.25K
	Stockholders Equity
12.71M	19.62M	23.18M	25.90M	5.64M
Cash Flow		Free Cash Flow
-5.88M	-2.50M	-3.14M	-4.09M	-3.17M
	Operating Cash Flow
-5.88M	-2.49M	-3.13M	-4.08M	-3.16M
	Investing Cash Flow
327.56K	-2.74M	-10.05K	-6.63K	-864.00
	Financing Cash Flow
829.00	-35.02K	-36.26K	26.49M	1.17M

Immuron Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.92
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMRN, the sentiment is Positive. The current price of 1.92 is above the 20-day moving average (MA) of 1.77, above the 50-day MA of 1.80, and below the 200-day MA of 2.12, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 58.22 is Neutral, neither overbought nor oversold. The STOCH value of 61.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMRN.

Immuron Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.36B	3.88	-42.93%	2.87%	17.85%	1.45%
PRTG	48 Neutral	$11.51M	―	-194.84%	―	―	48.91%
IMRN	47 Neutral	$9.94M	―	-52.79%	―	82.77%	-87.95%
RLMD	41 Neutral	$12.12M	―	-132.33%	―	―	19.21%
CTXR	38 Underperform	$7.56M	―	-52.85%	―	―	8.99%
BTAI	37 Underperform	$9.77M	―	82.91%	―	64.20%	73.71%
HOOK	32 Underperform	$16.16M	―	-61.68%	―	118.32%	61.16%